{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T20:46:19Z","timestamp":1786826779084,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.nmd.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:58:26Z","timestamp":1672952306000},"page":"139-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-2594","authenticated-orcid":false,"given":"Sarah","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schuelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Preu\u00dfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.nmd.2023.01.002_bib0001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.nmd.2023.01.002_bib0002","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.nmd.2023.01.002_bib0003","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2023.01.002_bib0004","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.01.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120084","article-title":"Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis","volume":"432","author":"Mirian","year":"2022","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.nmd.2023.01.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.nmd.2023.01.002_bib0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2023.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.nmd.2023.01.002_bib0009","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.nmd.2023.01.002_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodriguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2023.01.002_bib0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2023.01.002_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.605902","article-title":"Controversies in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.01.002_bib0013","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"Chan","year":"2007","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2023.01.002_bib0014","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.12270","article-title":"Antibodies to clustered acetylcholine receptor: expanding the phenotype","volume":"21","author":"Devic","year":"2014","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2023.01.002_bib0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2023.01.002_bib0016","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.nmd.2023.01.002_bib0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14737159.2021.1927715","article-title":"Improving laboratory diagnostics in myasthenia gravis","volume":"21","author":"Gastaldi","year":"2021","journal-title":"Expert Rev Mol Diagn"},{"issue":"1\u20132","key":"10.1016\/j.nmd.2023.01.002_bib0018","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","article-title":"A sensitive non-isotopic assay for acetylcholine receptor autoantibodies","volume":"364","author":"Hewer","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"10","key":"10.1016\/j.nmd.2023.01.002_bib0019","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.LAB.0000032379.63784.9C","article-title":"Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen","volume":"82","author":"Matthews","year":"2002","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.nmd.2023.01.002_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1086\/506257","article-title":"Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit","volume":"79","author":"Hoffmann","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.nmd.2023.01.002_bib0021","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12264-012-1256-0","article-title":"Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis","volume":"28","author":"Shi","year":"2012","journal-title":"Neurosci Bull"},{"issue":"12","key":"10.1016\/j.nmd.2023.01.002_bib0022","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/ene.13788","article-title":"Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence","volume":"25","author":"Gilhus","year":"2018","journal-title":"Eur J Neurol"},{"issue":"24","key":"10.1016\/j.nmd.2023.01.002_bib0023","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/01.wnl.0000336929.38733.7a","article-title":"Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis","volume":"71","author":"Oskoui","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2023.01.002_bib0024","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/mus.25154","article-title":"Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort","volume":"54","author":"Huda","year":"2016","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2023.01.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193723","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: autoantibody profiles and clinical features","volume":"13","author":"Park","year":"2018","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.nmd.2023.01.002_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.nmd.2023.01.002_bib0027","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.01.002_bib0028","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/mus.25591","article-title":"Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis","volume":"56","author":"Li","year":"2017","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2023.01.002_bib0029","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2023.01.002_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.nmd.2023.01.002_bib0031","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin","volume":"73","author":"Cortes-Vicente","year":"2016","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2023.01.002_bib0032","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2023.01.002_bib0033","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410120406","article-title":"Electrophysiological and clinical correlation in myasthenia gravis","volume":"12","author":"Oh","year":"1982","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.01.002_bib0034","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/mus.26390","article-title":"Repetitive nerve stimulation test in myasthenic crisis","volume":"59","author":"Oh","year":"2019","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.nmd.2023.01.002_bib0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.nmd.2009.09.005","article-title":"The difficulty in confirming clinical diagnosis of myasthenia gravis in a seronegative patient: a possible neurophysiological approach","volume":"19","author":"Caliandro","year":"2009","journal-title":"Neuromuscul Disord"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:46Z","timestamp":1760775226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0960896623000020"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.01.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}